Docetaxel with prednisone or prednisolone for the treatment of ...
Docetaxel with prednisone or prednisolone for the treatment of ...
Docetaxel with prednisone or prednisolone for the treatment of ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
140<br />
Appendix 6<br />
Study details and Participant details Intervention details Results Conclusion and<br />
design comments<br />
Outcome 6: Pain<br />
Not rep<strong>or</strong>ted<br />
Per protocol<br />
analysis<br />
perf<strong>or</strong>med:<br />
Not stated<br />
Outcome 7: HRQoL<br />
Not rep<strong>or</strong>ted<br />
Discontinuations: Not stated<br />
Patients were also required to have<br />
adequate pre<strong>treatment</strong> liver and<br />
cardiac function and ECOG<br />
perf<strong>or</strong>mance status <strong>of</strong> 0–2. No o<strong>the</strong>r<br />
malignancy in last 5 years,<br />
parenchymal brain metastases, pri<strong>or</strong><br />
immuno<strong>the</strong>rapy, pri<strong>or</strong> chemo<strong>the</strong>rapy<br />
<strong>or</strong> concurrent use <strong>of</strong> exogenous<br />
c<strong>or</strong>ticosteroids<br />
Comments: All<br />
patients given at<br />
least 1 dose included<br />
in analysis <strong>of</strong> safety.<br />
Study did not allow<br />
f<strong>or</strong> crossovers<br />
Baseline<br />
comparability: Yes<br />
Eligibility criteria<br />
specified: Yes<br />
Cointerventions:<br />
Anti-androgens<br />
where previously<br />
given. All o<strong>the</strong>r<br />
f<strong>or</strong>ms <strong>of</strong> h<strong>or</strong>mone<br />
<strong>the</strong>rapy were<br />
disallowed<br />
Blinding:<br />
Outcome<br />
assess<strong>or</strong>: No<br />
Carer: No<br />
Patient: No<br />
Success<br />
assessed: NA<br />
80% Follow-up:<br />
Yes